Understanding how fat and gut bacteria affect brain function and cognition

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between adipose tissue gene expression, blood metabolites, and gut microbiota in relation to cognitive function in individuals with and without obesity. It aims to explore how these factors influence memory, thinking, sleep, physical activity, and blood sugar regulation. Advanced technologies will be employed to analyze samples from participants scheduled for surgical extraction of adipose tissue, with the goal of identifying mechanisms through which obesity may impact brain function over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men and women \>20 years old.
* Scheduled for surgical intervention to extract adipose tissue.
* Signed informed consent for study participation.

Exclusion Criteria:

* Not meeting inclusion criteria.
* Non-obesity-related systemic diseases (cancer, severe kidney/liver disease).
* Systemic diseases with intrinsic inflammation (rheumatoid arthritis, Crohn's disease, asthma, chronic infections (HIV/tuberculosis)) or any type of infectious disease.
* Pregnant/breastfeeding women.
* Persons under legal/administrative restrictions.
* Those with infection symptoms in the past month.
* Use of antibiotics/antifungals/antivirals (previous 3 months).
* Chronic steroidal/anti-inflammatory drug use.
* Major psychiatric history.
* Excessive alcohol intake, acute or chronic (\>40g/day (women), \>80g/day (men)) or drug abuse.
* Immunosuppressants treatment.
* Participants with severe eating disorders.
* Serum liver enzymes (GOT, GPT) above twice the upper limit of normal. Obvious signs or symptoms of liver disease, acute or chronic hepatitis.
* History of iron balance disorders (e.g., genetic hemochromatosis, hemosiderosis from any cause, atransferrinemia, paroxysmal nocturnal hemoglobinuria).
* Creatinine greater than 1.2 and glomerular filtration rate below 40.
* Current treatment for malignant neoplasia, other than basal cell or squamous cell skin cancer.
* Heart disease classified as class III or IV, known ischemic cardiovascular disease.
* Renal failure, history of kidney transplant, or current dialysis treatment.
* Chronic constipation (bowel movement frequency ≥ 7 days) .

Where it's running

• Institut d'Investigació Biomèdica de Girona (IDIBGI)
  Girona, Girona, Spain Recruiting

Study contacts

• Principal investigator: José Manuel Fernández-Real, M.D., Ph.D. — Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
• Study coordinator: José Manuel Fernández-Real, M.D., Ph.D.
• Email: jmfreal@idibgi.org
• Phone: +34972940200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.